An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.This report is being filed on an international product, list number 6s60-23 (sars-cov-2 igg ii quant ) and has a similar product distributed in the us, list number 6s60-20/-30 (advisedx sars-cov-2 igg ii: eua#: (b)(4)).
|
The complaint investigation for a false negative sars-cov-2 igg ii quant result included a search for similar complaints, and the review of complaint text, trending data, labelling, and device history records.Additionally, in-house performance testing for reagent lot 36532fn00 was completed.Return testing was not performed as returns were not available.Device history record review on lot 36532fn00 did not show any potential non-conformances, or deviations associated with the customer¿s observation.Labelling was reviewed and found to adequately address the issue under review.In-house performance testing for reagent lot 36532fn00 was completed using a retained sample of the complaint lot.All specifications were met indicating the lot is performing acceptably.The reason for the negative result is unclear.Per the limitations of the procedure section of the package insert, immunocompromised patients who have covid-19 may have a delayed antibody response and produce levels of antibody which may not be detected as positive by the assay.However, in this case it was reported that the patient had no underlying conditions that may have contributed to a poor immune response.Per product labeling, higher titer antibody responses have been observed in patients with more severe illness as compared with mildly symptomatic or asymptomatic individuals.Based on the investigation, no systemic issue or deficiency of the sars-cov-2 igg ii quant reagent lot 36532fn00 was identified.This report is being filed on an international product, list number 6s60-23 (sars-cov-2 igg ii quant ) and has a similar product distributed in the us, list number 6s60-20/-30 (advisedx sars-cov-2 igg ii: eua # 203119).
|